December 2, 2020
Not all reductions in tumor size are equal (SITC 2020 poster)
Tumor shrinkage isn't always equal—our SITC 2020 analysis of 6,000+ NSCLC patients shows that the same reduction in tumor size predicts significantly better survival with PD-1/PD-L1 inhibitors compared to other therapies. This effect persists across PD-L1 expression levels, suggesting a unique survival benefit beyond tumor response alone...
.svg)
